Keenova Therapeutics Plc (MNK) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Customers, else..
 
Keenova Therapeutics Plc  (MNK)
 

Keenova Therapeutics Plc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MNK Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q1 MRQ) -7.42 % 12.22 % 8.91 % 10.9 %
Q / Q Revenue Growth (Q1 MRQ) - -2.93 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q1 TTM) -38.55 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q1 TTM) - 2.69 % 2.03 % 2.61 %
Revenue 5 Year Average Growth - 7.41 % 8.65 % 10.59 %


MNK's Growth Comparisons in I. Quarter 2026




Although the Major Pharmaceutical Preparations industry saw advancing Revenue by 12.22%, Keenova Therapeutics Plc announced -7.42% year on year sales decline in the first quarter 2026, to $ 468 millions, and underperformed the 8.91% Revenue growth in the Healthcare sector. Comparing the first quarter, sales Keenova Therapeutics Plc was trailing overall market not just Major Pharmaceutical Preparations industry.

Sequentially company's Revenue were unchanged from the fourth quarter results. . Looking into annual growth, sales grew by % on average in last five years, while S & P 500's including only Businesses with the first quarter 2026 earnings reports, average yearly sales growth is 10.59%.

MNK Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Rebates and Chargebacks
265.85 %
-
Product Returns
441.67 %
-
Other Sales Deductions
-77.31 %
-
Transferred at Point in Time
25.21 %
-
Transferred over Time
-58.28 %
-
Acthar Gel
46.88 %
-
Xiaflex
-
-
INOmax
-5.92 %
-
Amitiza
5 %
-
Other Products
764.84 %
-
License Revenue
2850 %
-
Total
11.36 %
-
Single Reportable
-
-


Growth Rates of MNK's Income in the first quarter 2026


MNK Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q1 MRQ) - -8.88 % 4.62 % 97.6 %
Sequential Operating Income Change (Q1 MRQ) - -4.52 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q1 TTM) - 30.63 % 30.73 % 40.67 %
Sequential Operating Income Growth (Q1 TTM) - -2.27 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change - 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q1 MRQ) - -34.9 % -25.98 % 90.69 %
Sequential Income from Cont. Ops. Change (Q1 MRQ) - -2.61 % -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q1 TTM) - 6.3 % 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q1 TTM) - -10.02 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - -0.55 % 0.17 % -28.52 %

MNK Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q1 MRQ) - -35.09 % -26.26 % 90.69 %
Q / Q Net Income Growth (Q1 MRQ) - 2.87 % -0.77 % 27.07 %
Y / Y Net Income Change (Q1 TTM) - 5.21 % 15.51 % 57.33 %
Sequential Net Income Change (Q1 TTM) - -10.17 % -6.72 % 18.65 %
Net Income 5 Year Avg. Growth - 14.55 % 9.21 % 22.96 %

MNK's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q1 MRQ) - -40.27 % -25.98 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q1 MRQ) - -7.72 % -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q1 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q1 TTM) - - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - -10.78 % 0.17 % -28.52 %



MNK EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q1 MRQ) - -40.45 % -26.26 % -28.52 %
Q / Q EPS Net Growth (Q1 MRQ) - -2.53 % -0.77 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q1 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q1 TTM) - - - 4.93 %
EPS Net 5 Year Avg. Change - 14.55 % 9.21 % 22.96 %



Keenova Therapeutics Plc reported bottom-line of $ -2.87 in the first quarter, compare to $ -1.33 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -40.45%, while Healthcare sector decreased by -26.26%, and overall market improved by 90.69%.

Sequentially company's EPS were unchanged from the fourth quarter results. . Looking into annual growth, income per share grew by % on average in the last five years, while the S & P 500's including only the businesses with the first quarter 2026 financial results, average yearly income per share growth is 22.96%.

MNK Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q1 MRQ) -89.25 % 25.53 % 48.49 % 48.62 %
Sequential Free Cash Flow Change (Q1 MRQ) - -42.37 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q1 TTM) - 11.91 % 18.61 % 60.27 %
Sequential Free Cash Flow Change (Q1 TTM) - 3.24 % 5.39 % 15.75 %
Free Cash Flow 5 Year Avg. Change - 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q1 MRQ) -90.25 % - - 339.02 %
Sequential Net Cash Flow Change (Q1 MRQ) -83.29 % - - 216.68 %
Y / Y Net Cash Flow Change (Q1 TTM) -62.4 % - - 209.43 %
Sequential Net Cash Flow Change (Q1 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q1 MRQ) -49.51 % 11.25 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q1 MRQ) -84.84 % -25.6 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q1 TTM) 106.05 % 16.65 % 7.87 % 109.38 %
Sequential Capital Expenditures Change (Q1 TTM) -6.37 % 2.92 % 1.6 % 23.05 %
Capital Expenditures 5 Year Avg. Change - 8.94 % 9.18 % 14.73 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.